The 2023 programme – which will support a cohort of UK healthtech organisations looking to upscale their US business – has been launched to leading healthtech organisations from across the UK at DACB’s global headquarters in The Walbrook Building, London.
As corporate sponsors, members of DACB’s market-leading health and technology teams will work closely with cohort members to ensure that from a UK legal perspective, they are fully prepared and ready to do business with the US HealthTech market. DACB will also accompany the cohort on tailored trade missions to key states in the US's thriving healthcare ecosystem.
Hamza Drabu, commercial partner who leads the DACB MedTech team, says, “This important partnership opportunity with the ABHI reinforces DACB’s focus on supporting clients to deliver improved patient outcomes, as well as working with dynamic and ambitious companies who have identified the programme as a platform to grow and expand their business.
"We are looking forward to building long-term relationships with members of the cohort while tapping into the huge amount of innovation coming out of US healthcare ecosystem for the benefit of our own clients."
